US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Champion Industries, Inc.

0.0001

+0.0000

Volume:- -

Turnover:- -

Market Cap:5.59

PE:0.00

High:0.0001

Open:0.0001

Low:0.0001

Close:0.0001

Loading ...

Overview Company News Filings

Novartis Gets CHMP Opinion for Label Expansion of Fabhalta

Lilly's Jaypirca Gets CHMP Nod for 2nd Leukemia Indication in Europe

AbbVie's Next Big Moneymaker? This Drug Just Took a Huge Step Toward Approval

Valneva reports positive CHMP opinion for adolescent label extension for Ixchiq

Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug

Eli Lilly Gets CHMP Backing of Jaypirca in Chronic Lymphocytic Leukemia

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

Biogen, Eisai announces CHMP of EMA reaffirmed positive opinion of lecanemab

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Krystal Biotech Gets CHMP Backing for Vyjuvek Approval

Krystal Biotech receives positive CHMP opinion for VYJUVEK

Press Release: Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK(R) for the Treatment of Dystrophic Epidermolysis Bullosa

Regeneron Gets CHMP Backing of Linvoseltamab in Multiple Myeloma

Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

AbbVie Gets CHMP Backing of Rinvoq in Giant Cell Arteritis

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CHMP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CHMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","market":"US","secType":"STK","nameCN":"Champion Industries, Inc.","latestPrice":0.0001,"timestamp":1744920000000,"preClose":0.0001,"halted":0,"volume":0,"delay":15,"floatShares":0,"shares":55857,"eps":-23.033406,"marketStatus":"Market Closed","change":0,"latestTime":"04-17 16:00:00 EDT Delay","open":0.0001,"high":0.0001,"low":0.0001,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-23.033406,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.0001,"volumeRatio":2.7777835648268714},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","floatShares":0,"roa":"-1.87%","roe":"-49.45%","lyrEps":-23.033406,"volumeRatio":2.7777835648268714,"shares":55857,"dividePrice":0,"high":0.0001,"amplitude":0,"preClose":0.0001,"low":0.0001,"week52Low":0.0001,"pbRate":"0.00","psRate":"0.00","week52High":0.0001,"institutionHeld":0,"latestPrice":0.0001,"eps":-23.033406,"divideRate":0,"volume":0,"delay":15,"ttmEps":-23.033406,"open":0.0001,"prevYearClose":0.0001,"prevWeekClose":0.0001,"prevMonthClose":0.0001,"prevQuarterClose":0.0001,"fiveDayClose":0.0001,"twentyDayClose":0.0001,"sixtyDayClose":0.0001},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHMP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516653171","title":"Novartis Gets CHMP Opinion for Label Expansion of Fabhalta","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653171","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516653171?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:39","pubTimestamp":1741012740,"startTime":"0","endTime":"0","summary":"Novartis NVS announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency has adopted a positive opinion for the label expansion of Fabhalta ((iptacopan).Fabhalta is an oral, Factor B inhibitor of the alternative complement pathway 6-7.The CHMP recommended granting a marketing authorization to Fabhalta for the treatment of adults with C3 glomerulopathy , an ultra-rare, progressive kidney disease with no currently approved treatments.A final decision from the European Commission  is expected in two months.The CHMP’s positive opinion is based on robust data from APPEAR-C3G, a randomized placebo-controlled phase III study. The study showed patients treated with Fabhalta, in addition to supportive care, achieved a statistically significant and clinically meaningful 35.1% reduction in proteinuria  at 6 months when compared to placebo.A potential approval will make Fabhalta the only drug indicated to target the underlying cause of C3G.Shares of Novartis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-gets-chmp-opinion-label-143900090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4583","BK4585","LU0889565916.HKD","LU1839511570.USD","LU0320765992.SGD","GILD","LU0109394709.USD","BK4568","IE00B3T34201.USD","LU1430594728.SGD","LU1571399168.USD","IE00B4R5TH58.HKD","LU0058720904.USD","IE00BJT1NW94.SGD","LU0211331839.USD","IE00B7SZLL34.SGD","BK4007","BK4532","IE00BKVL7J92.USD","BK4201","LU0234570918.USD","LU1066053197.SGD","IE0002141913.USD","LU2468319806.SGD","BK4578","BK4087","IE0002270589.USD","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","IE00B2B36J28.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","IE00B19Z3581.USD","BK4550","LU2087621335.USD","LU2089984988.USD","BK4588","IE00BFTCPJ56.SGD","NVS","EC","IE00BJJMRZ35.SGD","BK4139","LU1066051498.USD","IE0009355771.USD","CHMP","BMRN","LU1585245621.USD","BK4566"],"gpt_icon":0},{"id":"2516680448","title":"Lilly's Jaypirca Gets CHMP Nod for 2nd Leukemia Indication in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2516680448","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516680448?lang=en_us&edition=fundamental","pubTime":"2025-03-03 18:50","pubTimestamp":1740999000,"startTime":"0","endTime":"0","summary":"Eli Lilly and Company LLY announced that theEuropean Medicines Agency'sCommittee for Medicinal Productsfor Human Use  has given a positive opinion recommending approval of its BTK inhibitor, Jaypirca , for treating relapsed or refractory chronic lymphocytic leukemia  in patients who have been previously treated with a BTK inhibitor in the European Union. The approval was based on data from the phase III BRUIN CLL-321 study.The European Commission is expected to give its decision in a couple of months. Jaypirca is already approved in the EU on a conditional basis for the treatment of adult patients with relapsed or refractory mantle cell lymphoma  who have been previously treated with a BTK inhibitor.Lilly’s shares have risen 16.2% in the past year against a decline of 0.9% for the industry.Jaypirca was approved in the United States for treating CLL or small lymphocytic lymphoma in patients who have received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lillys-jaypirca-gets-chmp-nod-105000850.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE000M9KFDE8.USD","LU0354030438.USD","LU2361044865.SGD","LU2237443622.USD","ABBV","LU1244550577.SGD","SG9999003800.SGD","LU0320765059.SGD","LU0345769631.USD","SGXZ51526630.SGD","LU2237443382.USD","LU0256863811.USD","IE0009355771.USD","IE00BVYPNV92.GBP","SG9999013999.USD","JNJ","LU0128525929.USD","LU0061475181.USD","LU1066051498.USD","LU1935042991.SGD","IE00BVYPNW00.USD","IE0004445239.USD","LU1059921491.USD","LU2087621335.USD","LU1720051108.HKD","GB00BDT5M118.USD","LU0058720904.USD","AZN","LU1917777945.USD","LU1244550221.USD","CHMP","LU2430703095.HKD","SG9999002224.SGD","LLY","LU0320765646.SGD","LU2129689514.USD","LU0882574055.USD","SGXZ99366536.SGD","LU1267930730.SGD","LU1989772840.SGD","LU1196500208.SGD","LU2129689605.HKD","LU0198837287.USD","LU2347655156.SGD","SG9999001176.SGD","LU1267930813.SGD","LU1720051017.SGD","LU1064131342.USD","SG9999001176.USD","SG9999015945.SGD"],"gpt_icon":1},{"id":"2516055533","title":"AbbVie's Next Big Moneymaker? This Drug Just Took a Huge Step Toward Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2516055533","media":"GuruFocus.com","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516055533?lang=en_us&edition=fundamental","pubTime":"2025-03-01 03:32","pubTimestamp":1740771164,"startTime":"0","endTime":"0","summary":"AbbVie  just got a major nod from European regulators, setting the stage for what could be a game-changing approval. The European Medicines Agency's Committee for Medicinal Products for Human Use  has issued a positive opinion on upadacitinib  for treating giant cell arteritis , an autoimmune disease that can lead to blindness and stroke. If the European Commission follows suit in the first half of 2025, upadacitinib would become the first and only oral advanced therapy for GCAa huge win for AbbVie as it looks to expand its immunology dominance.With the immunology space heating up and competition fierce, AbbVie's ability to secure regulatory wins in new areas will be critical for its long-term trajectory. The European Commission's final decision will be the moment of truth. A green light would not only boost AbbVie's revenue potential but also solidify its standing in the high-stakes biopharma race. Investors betting on AbbVie's next leg of growth will be watching this one closely.This","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvies-next-big-moneymaker-drug-193244203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0689472784.USD","ABBV","LU2087621335.USD","LU1989771016.USD","SG9999015986.USD","LU0912757837.SGD","LU0417517546.SGD","LU0198837287.USD","LU1061106388.HKD","LU0943347566.SGD","IE00BVYPNV92.GBP","LU1037948897.HKD","LU1093756168.USD","LU1551013425.SGD","BK4559","LU2237443549.SGD","BK4581","LU0211327993.USD","LU0861579265.USD","BK4087","LU0234572021.USD","LU0029864427.USD","LU0882574055.USD","LU1934455194.USD","BK4534","LU0256863811.USD","CHMP","LU1037948541.HKD","IE0009355771.USD","LU0820561818.USD","LU1057294990.SGD","LU0203345920.USD","SG9999015945.SGD","LU1551013342.USD","LU2237443978.SGD","LU0949170772.SGD","LU1430594728.SGD","IE00BGHQF631.EUR","LU2237443622.USD","LU0545039389.USD","LU1244550221.USD","IE0002141913.USD","LU0553294199.USD","SG9999001440.SGD","LU1585245621.USD","LU0965509283.SGD","IE00B2B36J28.USD","BK4533","LU0203347892.USD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2516744163","title":"Valneva reports positive CHMP opinion for adolescent label extension for Ixchiq","url":"https://stock-news.laohu8.com/highlight/detail?id=2516744163","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516744163?lang=en_us&edition=fundamental","pubTime":"2025-03-01 00:50","pubTimestamp":1740761409,"startTime":"0","endTime":"0","summary":"Valneva (VALN) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/valneva-reports-positive-chmp-opinion-for-adolescent-label-extension-for-ixchiq?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/valneva-reports-positive-chmp-opinion-for-adolescent-label-extension-for-ixchiq?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4087","CHMP","VALN","BK4139"],"gpt_icon":0},{"id":"2516712473","title":"Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®","url":"https://stock-news.laohu8.com/highlight/detail?id=2516712473","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516712473?lang=en_us&edition=fundamental","pubTime":"2025-03-01 00:45","pubTimestamp":1740761100,"startTime":"0","endTime":"0","summary":"If granted, IXCHIQ will become the first vaccine against the chikungunya virus  available in the EU for adolescents 12 years of age and older. Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, said, “Given the substantial risk that chikungunya presents to individuals residing in or traveling to endemic regions, it's imperative to ensure the vaccine is available to all age groups. Therefore, this positive CHMP opinion marks a crucial milestone toward introducing a more robust preventative solution against chikungunya in the EU. Broader accessibility will help provide protection and mitigate the burden of this debilitating illness, which is continuing to spread in areas that were previously unaffected.”The CHMP positive opinion follows four regulatory approvals in the U.S6., Europe7, Canada8 and the UK9 in adults 18 years of age and older. Valneva expects to receive marketing approval in Brazil in the first quarter of 2025, which would represent the first approval in an ende","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-receives-ema-positive-chmp-164500042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","VALN","CHMP","BK4135","CEPI","BK4539","BK4087","BK4156","EC","INRLF","BK4201","SII"],"gpt_icon":0},{"id":"2516737941","title":"Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older","url":"https://stock-news.laohu8.com/highlight/detail?id=2516737941","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516737941?lang=en_us&edition=fundamental","pubTime":"2025-03-01 00:14","pubTimestamp":1740759240,"startTime":"0","endTime":"0","summary":"First chikungunya vaccine approved in Europe for persons as young as 12 years old.On track for launch in key European markets in the first half of 2025.COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S  today announced that the European Commission has granted marketing authorization in Europe for VIMKUNYA for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older.The marketing authorization was granted by the European Commission upon recommendation by the Committee for Medicinal Products for Human Use  of the European Medicines Agency  in January 2025 and was based on results from two phase 3 clinical trials which enrolled more than 3,500 healthy individuals 12 years of age and older. The studies met their primary endpoints, with results showing that 21 days after vaccination, the vaccine induced neutralizing antibodies in up to 97.8% of the vaccinated individuals and demonstrated a rapid immune response starting to de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bavarian-nordic-receives-marketing-authorization-161400126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4087","BK4215","BK4139","CHMP","VLP","MAA","BK4588","BVNRY","BVNKF","BK4585"],"gpt_icon":0},{"id":"2514537332","title":"Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2514537332","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514537332?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:52","pubTimestamp":1740754320,"startTime":"0","endTime":"0","summary":"Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi.The companies on Friday said the European Commission, which had asked the panel to consider information on the safety of Leqembi that became available after it adopted a positive opinion in November, will resume its decision-making process for the drug's marketing authorization.The commission last month asked the CHMP to consider whether the new information would require an update of the positive opinion, and to consider whether the wording of the risk minimization measures in the opinion is clear enough to ensure correct implementation.Biogen and Eisai on Friday said the CHMP concluded that its positive opinion didn't need to be updated.The CHMP last July recommended against approval of Leqembi, citing safety and efficacy issues, but Biogen and Eisai asked the panel to take another look, and the CHMP in November ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BIIB","LU0109394709.USD","LU0234570918.USD","LU0889565916.HKD","BK4139","BK4533","IE00B894F039.SGD","LU0320765992.SGD","BK4087","IE00B19Z9P08.USD","CHMP","IE00B19Z9Z06.USD","BK4532","BK4588"],"gpt_icon":0},{"id":"2514732264","title":"Eli Lilly Gets CHMP Backing of Jaypirca in Chronic Lymphocytic Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2514732264","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514732264?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:59","pubTimestamp":1740751140,"startTime":"0","endTime":"0","summary":"Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic leukemia.Eli Lilly on Friday said the recommendation covers Jaypirca for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia who have been previously treated with a Bruton's tyrosine kinase inhibitor.The Indianapolis drugmaker said the European Commission, which generally follows the CHMP's advice, is expected to make a final decision in the next one to two months.Eli Lilly previously won conditional European approval for Jaypirca in adults with relapsed or refractory mantle cell lymphoma who have been previously treated with a BTK inhibitor.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU2361045086.USD","LU0354030438.USD","IE00BK4W5M84.HKD","LU0096364046.USD","LU2237443382.USD","LU0882574139.USD","LU0106261372.USD","LU1868836757.USD","LU1023059063.AUD","SG9999015986.USD","BK4534","SG9999013999.USD","CHMP","LU2361044949.HKD","BK4585","LU1623119135.USD","LU2106854487.HKD","BK4599","LU1093756325.SGD","LU1974910355.USD","LU1983299246.USD","LU0203202063.USD","LU0672654240.SGD","SG9999018857.SGD","LU1720051017.SGD","LU0238689110.USD","SG9999014906.USD","SG9999015945.SGD","LU2237443622.USD","LLY","LU1061106388.HKD","LU0466842654.USD","SG9999018865.SGD","SG9999001176.SGD","LU0256863902.USD","LU1868837300.USD","SGXZ81514606.USD","LU0417517546.SGD","LU0708995401.HKD","LU2602419157.SGD","LU2264538146.SGD","SGXZ51526630.SGD","LU1917777945.USD","LU1035775433.USD","LU1989771016.USD","LU2324357040.USD","LU0456855351.SGD","IE0002141913.USD","LU0079474960.USD"],"gpt_icon":1},{"id":"2514032464","title":"The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2514032464","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514032464?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:23","pubTimestamp":1740748980,"startTime":"0","endTime":"0","summary":"TOKYO and CAMBRIDGE, Mass., Feb. 28, 2025 /PRNewswire/ -- Eisai Co., Ltd.  and Biogen Inc.  announced today that the Committee for Medicinal Products for Human Use  of the European Medicines Agency has reaffirmed its positive opinion by consensus for theanti-Aβ monoclonal antibody lecanemab, adopted in November 2024.1 Following CHMP's reaffirmation, after having considered the additional information requested by the European Commission , the EC will resume the decision-making process for lecanemab's marketing authorization.Lecanemabhas been approved in the U.S.,3Japan,4China,5South Korea,6 Hong Kong,7Israel,8the United Arab Emirates,9the United Kingdom,10 Mexico,11 Macau and Oman,and is under regulatory review in 18 countries and regions including the EU. In January2025,the U.S. Food and Drug Administration  has approved the Supplemental Biologics License Application  for once every four weeks maintenancedosing. In January2025, the submission of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/committee-medicinal-products-human-chmp-132300937.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/committee-medicinal-products-human-chmp-132300937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHMP","BIIB","BK4087","BK4201","BK4585","BK4533","IE00B19Z9P08.USD","IE00B894F039.SGD","BK4139","LU0234570918.USD","EC","LU0889565916.HKD","IE00B19Z9Z06.USD","LU0109394709.USD","MCI","LU0320765992.SGD","BK4588","BK4532"],"gpt_icon":0},{"id":"2514321173","title":"Biogen, Eisai announces CHMP of EMA reaffirmed positive opinion of lecanemab","url":"https://stock-news.laohu8.com/highlight/detail?id=2514321173","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514321173?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:17","pubTimestamp":1740748632,"startTime":"0","endTime":"0","summary":"Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biogen-eisai-announces-chmp-of-ema-reaffirmed-positive-opinion-of-lecanemab?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biogen-eisai-announces-chmp-of-ema-reaffirmed-positive-opinion-of-lecanemab?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","BK4007","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","CHMP","IE00B894F039.SGD","LU0234570918.USD","ESAIY","LU0109394709.USD","BIIB","BK4532","LU0889565916.HKD","BK4588","BK4585","BK4139","BK4087","BK4533"],"gpt_icon":0},{"id":"2514324925","title":"Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2514324925","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514324925?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:14","pubTimestamp":1740748440,"startTime":"0","endTime":"0","summary":"The positive opinion is based on results from the Phase 3 BRUIN CLL-321 trial, recently presented at the 2024 American Society of Hematology Annual Meeting. BRUIN CLL-321 is the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor. The positive opinion is supported by data from the BRUIN CLL-321 clinical trial, the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor. The study's primary endpoint of progression-free survival  was met at the prespecified time of final analysis , based on independent review committee  assessment, demonstrating pirtobrutinib was superior to investigator's choice of idelalisib plus rituximab  or bendamustine plus rituximab , both global standards of care.1 At an updated analysis , pirtobrutinib reduced therisk of disease progressionor death by 46% compared to IdelaR or BR, consistent with the primary analysis.PFS results were cons","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lillys-jaypirca-pirtobrutinib-recommended-chmp-131400700.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lillys-jaypirca-pirtobrutinib-recommended-chmp-131400700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0882574139.USD","LU2063271972.USD","LU1061106388.HKD","LU0203201768.USD","BK4599","LU2237443465.HKD","LU2211815571.USD","CHMP","ORR","LU2237443622.USD","LU2265009873.SGD","LU2361045086.USD","BK4585","BNTX","BK4533","LU2491050071.SGD","SG9999015986.USD","LU1267930730.SGD","IE0002141913.USD","ASH","BK4516","LU2237443978.SGD","BK4226","LLY","BK4094","BK4109","LU0354030511.USD","LU0238689110.USD","LU1023059063.AUD","IE00BJT1NW94.SGD","LU1974910355.USD","FL","LU1069344957.HKD","LU1814569148.SGD","LU2237443382.USD","LU1720051108.HKD","OS","LU0640476718.USD","LU0390134368.USD","BK4588","LU0203202063.USD","LU2602419157.SGD","PRO","SG9999001176.USD","LU0471298777.SGD","LU2461242641.AUD","IE00BK4W5L77.USD","PFS","BR","IE0009355771.USD"],"gpt_icon":1},{"id":"2514623324","title":"The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2514623324","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514623324?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:12","pubTimestamp":1740748320,"startTime":"0","endTime":"0","summary":"STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- BioArctic AB's   partner Eisai today announced today that the Committee for Medicinal Products for Human Use  of the European Medicines Agency has reaffirmed its positive opinion for the anti-Aβ monoclonal antibody lecanemab , adopted in November 2024. Following CHMP's reaffirmation, after having considered the additional information requested by the European Commission , the EC will resume the decision-making process for lecanemab's marketing authorisation.If the EC approves the lecanemab marketing authorization application, the approval will apply to all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway. Leqembi is already approved in the US, Japan, China, Great Britain and other markets. Eisai and BioArctic will continue to make every effort to deliver lecanemab to patients with early AD in as soon as possible.Lecanemab is approved in the U.S., Japan, China, United Kingdom, and several other markets for the treatm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/committee-medicinal-products-human-chmp-131200104.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/committee-medicinal-products-human-chmp-131200104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4087","EC","CHMP","BRCTF","BK4201","BK4139","MCI","BK4156"],"gpt_icon":0},{"id":"2514329672","title":"ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2514329672","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514329672?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:00","pubTimestamp":1740747600,"startTime":"0","endTime":"0","summary":"Recommendation based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year. TOKYO & MUNICH, February 28, 2025----Daiichi Sankyo  and AstraZeneca’s  ENHERTU  has been recommended for approval in the European Union  as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor  positive, HER2 low  or HER2 ultralow  breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate  discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.In the DESTINY-Breast06 trial, ENHERTU demonstrated a 38% reduction in the risk of disease progression or death versus chemotherapy in patients with chemotherapy-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enhertu-recommended-approval-eu-chmp-130000849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ORR","BK4087","BK4156","BK4211","BK4203","BK4231","BK4195","PBD","PFS","DSNKY","DSKYF","BK4225","BK4007","BK4080","CHMP","HR","ADC"],"gpt_icon":0},{"id":"2514321361","title":"Krystal Biotech Gets CHMP Backing for Vyjuvek Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2514321361","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514321361?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:58","pubTimestamp":1740747480,"startTime":"0","endTime":"0","summary":"Krystal Biotech said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Vyjuvek topical gene therapy for certain patients with the rare genetic skin disorder dystrophic epidermolysis bullosa, or DEB.Krystal on Friday said the recommendation covers Vyjuvek for the treatment of wounds in people with DEB who have mutations in the collagen type VII alpha 1 chain gene, starting from birth.The Pittsburgh biotechnology company said it expects a final decision from the European Commission, which generally follows the CHMP's advice, in the second quarter.Krystal, which won U.S. Food and Drug Administration approval of Vyjuvek in 2023, recorded $290.5 million in net product revenue for the drug last year.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHMP","KRYS","BK4139","BK4087"],"gpt_icon":0},{"id":"2514326946","title":"Krystal Biotech receives positive CHMP opinion for VYJUVEK","url":"https://stock-news.laohu8.com/highlight/detail?id=2514326946","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514326946?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:45","pubTimestamp":1740746738,"startTime":"0","endTime":"0","summary":"Krystal Biotech (KRYS) welcomed the European Medicines Agency’s announcement that its Committee for Medicinal Products for Human Use has issued a p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/krystal-biotech-receives-positive-chmp-opinion-for-vyjuvek?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/krystal-biotech-receives-positive-chmp-opinion-for-vyjuvek?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KRYS","CHMP","BK4139","BK4087"],"gpt_icon":0},{"id":"2514326561","title":"Press Release: Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK(R) for the Treatment of Dystrophic Epidermolysis Bullosa","url":"https://stock-news.laohu8.com/highlight/detail?id=2514326561","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514326561?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:40","pubTimestamp":1740746400,"startTime":"0","endTime":"0","summary":"Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa. EC approval decision anticipated in second quarter of 2025. PITTSBURGH, Feb. 28, 2025  -- Krystal Biotech, Inc.  , a commercial-stage biotechnology company, today welcomed the European Medicines Agency's  announcement that its Committee for Medicinal Products for Human Use  has issued a positive recommendation for the European Commission  to approve VYJUVEK  for the treatment of wounds in patients with dystrophic epidermolysis bullosa  who have mutations in the collagen type VII alpha 1 chain  gene, starting from birth. The CHMP's positive opinion includes support for administration of VYJUVEK in either a health care setting  or at home. If deemed appropriate by a healthcare professional, trained patients or caregivers may also apply VYJUVEK.The final EC decision is anticipated in the second quarter of 2025. The decision will be applicable to all European Union member state","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","R","BK4201","BK4232","CHMP","BK4087","KRYS","BK4022","BK4139"],"gpt_icon":0},{"id":"2514326082","title":"Regeneron Gets CHMP Backing of Linvoseltamab in Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2514326082","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514326082?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:34","pubTimestamp":1740746040,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended conditional marketing approval of linvoseltamab for certain adults with the blood cancer multiple myeloma.Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have shown disease progression on the last therapy.The Tarrytown, N.Y., biotechnology company said the European Commission, which generally follows the CHMP's advice, is expected to announce a final decision in the coming months.The U.S. Food and Drug Administration earlier this month accepted Regeneron's resubmitted application seeking approval of linvoseltamab and set a target action date of July 10 for a decision.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362540622.SGD","BK4585","LU0889565916.HKD","LU2023250504.SGD","LU0882574055.USD","LU2362541513.USD","LU2106854487.HKD","LU0109394709.USD","LU0053666078.USD","LU0823416689.USD","LU0058720904.USD","LU2468319806.SGD","BK4087","REGN","LU0289739699.SGD","LU0114720955.EUR","LU1917777945.USD","LU2362541273.HKD","LU2089984988.USD","BK4588","BK4139","LU2237438978.USD","CHMP","LU1974910355.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2514325183","title":"Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations","url":"https://stock-news.laohu8.com/highlight/detail?id=2514325183","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514325183?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:22","pubTimestamp":1740745320,"startTime":"0","endTime":"0","summary":"-If approved, approximately 4,000 people with cystic fibrosis in the European Union will be eligible for a medicine that treats the underlying cause of their disease for the first time-. \"We are thrilled by the positive CHMP opinion in support of expanding the KAFTRIO in combination with ivacaftor indication to include all CF patients 2 years and older who make CFTR protein,\" said Fosca De Iorio, M.D., Vice President, International Medical Affairs at Vertex. \"If approved, thousands of additional patients across Europe will be eligible for a CFTR modulator, bringing us closer than ever to our goal of getting treatments that address the underlying cause of the disease to all people living with CF.\". Today Vertex’s CF medicines are treating over 68,000 people with CF across more than 60 countries on six continents. This represents 2/3 of the diagnosed people with CF eligible for CFTR modulator therapy.Diagnosis of CF is often made by genetic testing and is confirmed by testing sweat c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vertex-receives-chmp-positive-opinion-122200046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","LU2462157665.USD","LU0061475181.USD","BK4532","LU2362540622.SGD","CHMP","CF","BK4087","IE00B19Z9Z06.USD","BK4138","LU1430594728.SGD","BK4585","BK4533","LU0079474960.USD","IE00B2B36J28.USD","BK4139","LU0417517546.SGD","VTNR","LU2362541273.HKD","IE0002141913.USD","IE00B19Z3B42.SGD","VERX","LU0058720904.USD","LU2237438978.USD","LU1093756168.USD","LU2362541513.USD","LU1035775433.USD","LU0256863811.USD","BK4567","IE00B19Z9P08.USD","IE00BFTCPJ56.SGD","LU1559883803.SGD","IE0002270589.USD","LU1585245621.USD","IE00BJT1NW94.SGD","IE00B19Z3581.USD","LU1069344957.HKD","LU0889565916.HKD","LU2456880835.USD","LU0234570918.USD","IE00BJJMRZ35.SGD","LU0289739699.SGD","VRTX","BK4588","IE00B894F039.SGD","LU0757428866.USD","IE00B4R5TH58.HKD","LU0109394709.USD","IE00BZ9MQY76.HKD","IE0009355771.USD"],"gpt_icon":0},{"id":"2514960323","title":"Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2514960323","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514960323?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:00","pubTimestamp":1740744000,"startTime":"0","endTime":"0","summary":"TARRYTOWN, N.Y., Feb. 28, 2025  -- Regeneron Pharmaceuticals, Inc.  today announced that the European Medicines Agency’s  Committee for Medicinal Products for Human Use  has adopted a positive opinion recommending conditional marketing authorization of linvoseltamab to treat adults with relapsed and refractory (R/R) multiple myeloma . The recommendation is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy. The European Commission is expected to announce a final decision in the coming months.Linvoseltamab is investigational and has not been approved by any regulatory authority.Eligibility in the Phase 2 portion requires patients to have received at least three prior lines of therapy or have triple-class refractory MM. Linvoseltamab is administered with an initial step-up dosing regimen followed by the full 200 m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/linvoseltamab-recommended-eu-approval-chmp-120000259.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0053666078.USD","LU0114720955.EUR","BK4139","LU1917777945.USD","LU0289739699.SGD","LU0823416689.USD","BK4156","LU1974910355.USD","LU0058720904.USD","BK4588","LU2237438978.USD","BK4087","BK4585","LU2362541513.USD","REGN","LU2023250504.SGD","LU0889565916.HKD","LU0882574055.USD","LU2362540622.SGD","LU0109394709.USD","CHMP","LU2468319806.SGD","LU2362541273.HKD","LU0320765992.SGD","EU","LU2106854487.HKD","LU2089984988.USD"],"gpt_icon":0},{"id":"2514323644","title":"AbbVie Gets CHMP Backing of Rinvoq in Giant Cell Arteritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2514323644","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514323644?lang=en_us&edition=fundamental","pubTime":"2025-02-28 19:34","pubTimestamp":1740742440,"startTime":"0","endTime":"0","summary":"AbbVie said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis.AbbVie on Friday said a green light would make Rinvoq the first and only oral advanced therapy for the inflammatory disease that can cause headache, jaw pain and changes in vision, including sudden and permanent vision loss.The North Chicago, Ill., biopharmaceutical company said the European Commission, which generally follows the CHMP's advice, is expected to make a final decision in the first half of the year.AbbVie in late January said it expects Rinvoq revenue to top $11 billion in 2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0256863902.USD","LU1551013342.USD","LU1934455277.USD","LU0738911758.USD","IE00BSNM7G36.USD","LU1934455194.USD","LU2468319806.SGD","BK4581","LU0820561818.USD","BK4139","LU2237443549.SGD","IE00B2B36J28.USD","LU0198837287.USD","LU0965508806.USD","LU0689472784.USD","SG9999015978.USD","LU0949170772.SGD","LU1093756325.SGD","LU1732800096.USD","LU0211328371.USD","IE00B4R5TH58.HKD","BK4585","LU0128525929.USD","LU0553294199.USD","IE00B3PB1722.GBP","LU0820561909.HKD","IE0002141913.USD","LU1057294990.SGD","LU1839511570.USD","SG9999001440.SGD","LU1244550577.SGD","LU2237443978.SGD","IE00BVYPNV92.GBP","LU1023059063.AUD","LU0456855351.SGD","SG9999015945.SGD","LU2237443382.USD","LU1989771016.USD","LU0170899867.USD","LU2087621335.USD","CHMP","LU0234572021.USD","LU1061106388.HKD","ABBV","SG9999015986.USD","LU1037948897.HKD","LU0158827948.USD","LU0882574055.USD","LU0795875169.SGD","LU0114720955.EUR"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":126,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHMP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHMP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CHMP\",market:\"US\",delay:false,,,undefined,":{}}}